West Pharmaceutical Services to Announce Q4 2025 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy WST?
Source: seekingalpha
West Pharmaceutical Services Inc. (WST) experienced a decline of 3.37% and hit a 20-day low amid broader market weakness, with the Nasdaq-100 down 0.56% and the S&P 500 down 0.27%.
The company is set to release its Q4 and full-year 2025 financial results on February 12, 2026, which is expected to significantly impact investor sentiment. Following the earnings release, a conference call will be held to discuss the results and business expectations. In fiscal year 2024, West generated $2.89 billion in net sales, reinforcing its position as a leading provider of innovative injectable solutions.
This upcoming earnings report could provide critical insights into the company's performance and future outlook, potentially influencing stock movement in the near term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 322.010
Low
285.00
Averages
348.70
High
375.00
Current: 322.010
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical Services to Present at Upcoming Investor Conferences
- Investor Conference Schedule: West Pharmaceutical Services will participate in the Bank of America Global Healthcare Conference on May 12, 2026, and the William Blair Annual Growth Stock Conference on June 2, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's visibility.
- Webcast Availability: The live webcasts for these events will be accessible in the Investors section of the company's website, with replays available for approximately 90 days post-event, enhancing transparency and fostering interaction with potential investors.
- Company Performance Overview: West reported net sales of $3.07 billion in fiscal year 2025, demonstrating strong performance in the global injectable solutions market, further solidifying its position as an industry leader.
- Global Business Footprint: With over 10,000 employees across 50 sites, including 26 manufacturing facilities, West delivers over 41 billion components and devices annually, enabling effective support for drug developers and enhancing its competitive edge in the market.
See More
Analysis of WST Dividend Expectations and Stock Performance
- Dividend Yield Analysis: WST's estimated annualized dividend yield stands at 0.29%, and while dividends are not always predictable, historical data aids in assessing the likelihood of future dividends, thereby influencing investor return expectations.
- Stock Price Range: WST's 52-week low is $202.79 per share, with a high of $322.34, and the latest trade at $308.61 indicates that the stock is fluctuating near its high, which may affect investors' buying decisions.
- ETF Holding Proportion: According to ETF Channel, WST constitutes 4.44% of the Virtus KAR Mid-Cap ETF (KMID), which is trading down about 0.4% on the day, potentially reflecting overall market sentiment towards mid-cap stocks.
- Intraday Stock Performance: In Monday trading, shares of West Pharmaceutical Services, Inc. are up about 0.7%, indicating a positive short-term market reaction to the company, which may attract more investor attention.
See More
BARCLAYS INCREASES TARGET PRICE FOR WEST PHARMACEUTICAL SERVICES INC TO $310, UP FROM $275
Company Overview: West Pharmaceutical Services is a key player in the pharmaceutical industry, providing essential services and products.
Target Price Increase: Barclays has raised the target price for West Pharmaceutical Services from $275 to $310, indicating a positive outlook for the company's stock.
See More
Semiconductor Stocks Overbought Amid Market Rally
- Semiconductor Surge: Semiconductor stocks emerged as a focal point for investors this week, with the S&P 500 and Nasdaq rising 0.55% and 1.50% respectively, pushing the market to new highs and reflecting strong optimism in the sector.
- Overbought Indicators: CNBC Pro's analysis identified stocks with a 14-day RSI above 70 as overbought, indicating potential pullback risks, particularly as the iShares Semiconductor ETF (SOXX) posted an 11.04% gain this week, showcasing robust enthusiasm for chipmakers.
- Earnings Drive: Texas Instruments reported first-quarter earnings that exceeded expectations, highlighting strong demand for its analog chips, which significantly boosted its stock price and reinforced market confidence in the semiconductor industry.
- Narrowing Market Leadership: Cameron Dawson, Chief Investment Officer at NewEdge Wealth, noted that market leadership is increasingly concentrated in the semiconductor sector, indicating a sustained rise in investor focus on this industry, which may impact the performance of other sectors.
See More
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
- Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
- Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
- Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
- Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
See More
US Stocks Slightly Up, Led by Chipmakers
- Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
- Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
- Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
- Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
See More
West Pharmaceutical Services to Present at Upcoming Investor Conferences
- Investor Conference Schedule: West Pharmaceutical Services will participate in the Bank of America Global Healthcare Conference on May 12, 2026, and the William Blair Annual Growth Stock Conference on June 2, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's visibility.
- Webcast Availability: The live webcasts for these events will be accessible in the Investors section of the company's website, with replays available for approximately 90 days post-event, enhancing transparency and fostering interaction with potential investors.
- Company Performance Overview: West reported net sales of $3.07 billion in fiscal year 2025, demonstrating strong performance in the global injectable solutions market, further solidifying its position as an industry leader.
- Global Business Footprint: With over 10,000 employees across 50 sites, including 26 manufacturing facilities, West delivers over 41 billion components and devices annually, enabling effective support for drug developers and enhancing its competitive edge in the market.
See More
Analysis of WST Dividend Expectations and Stock Performance
- Dividend Yield Analysis: WST's estimated annualized dividend yield stands at 0.29%, and while dividends are not always predictable, historical data aids in assessing the likelihood of future dividends, thereby influencing investor return expectations.
- Stock Price Range: WST's 52-week low is $202.79 per share, with a high of $322.34, and the latest trade at $308.61 indicates that the stock is fluctuating near its high, which may affect investors' buying decisions.
- ETF Holding Proportion: According to ETF Channel, WST constitutes 4.44% of the Virtus KAR Mid-Cap ETF (KMID), which is trading down about 0.4% on the day, potentially reflecting overall market sentiment towards mid-cap stocks.
- Intraday Stock Performance: In Monday trading, shares of West Pharmaceutical Services, Inc. are up about 0.7%, indicating a positive short-term market reaction to the company, which may attract more investor attention.
See More
BARCLAYS INCREASES TARGET PRICE FOR WEST PHARMACEUTICAL SERVICES INC TO $310, UP FROM $275
Company Overview: West Pharmaceutical Services is a key player in the pharmaceutical industry, providing essential services and products.
Target Price Increase: Barclays has raised the target price for West Pharmaceutical Services from $275 to $310, indicating a positive outlook for the company's stock.
See More
Semiconductor Stocks Overbought Amid Market Rally
- Semiconductor Surge: Semiconductor stocks emerged as a focal point for investors this week, with the S&P 500 and Nasdaq rising 0.55% and 1.50% respectively, pushing the market to new highs and reflecting strong optimism in the sector.
- Overbought Indicators: CNBC Pro's analysis identified stocks with a 14-day RSI above 70 as overbought, indicating potential pullback risks, particularly as the iShares Semiconductor ETF (SOXX) posted an 11.04% gain this week, showcasing robust enthusiasm for chipmakers.
- Earnings Drive: Texas Instruments reported first-quarter earnings that exceeded expectations, highlighting strong demand for its analog chips, which significantly boosted its stock price and reinforced market confidence in the semiconductor industry.
- Narrowing Market Leadership: Cameron Dawson, Chief Investment Officer at NewEdge Wealth, noted that market leadership is increasingly concentrated in the semiconductor sector, indicating a sustained rise in investor focus on this industry, which may impact the performance of other sectors.
See More
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
- Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
- Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
- Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
- Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
See More
US Stocks Slightly Up, Led by Chipmakers
- Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
- Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
- Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
- Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
See More
